10-Q: Oramed Pharmaceuticals Reports Q1 2024 Results, Driven by Financial Gains and Strategic Review

Oramed Pharmaceuticals reported a net income of $1.534 million for the first quarter of 2024, a significant turnaround from a net loss in the same period last year, primarily due to financial income from investments.

Summary

• Oramed Pharmaceuticals reported a net income of $1.534 million for the quarter ended March 31, 2024, compared to a net loss of $3.611 million for the same period in 2023.
• The company's financial income, net, increased to $5.088 million, up from $1.597 million in the prior year, primarily due to the revaluation of the Scilex transaction and interest from short-term bank deposits.
• Research and development expenses decreased significantly by 73% to $1.179 million, down from $4.427 million in the same period last year, due to the termination of Phase 3 trials.
• General and administrative expenses increased by 41% to $1.783 million, compared to $1.263 million in the prior year, mainly due to higher stock-based compensation expenses.
• The company's cash and cash equivalents increased to $18.576 million, up from $9.055 million at the end of 2023.
• Oramed is working on a new Phase 3 clinical trial protocol for oral insulin, based on analysis of previous trial data that showed positive responses in specific patient subpopulations.
• The company has entered into a joint venture agreement with HTIT Biotech to develop and commercialize products based on Oramed's oral drug delivery technology, with HTIT contributing $70 million and Oramed contributing $20 million in cash and shares, plus intellectual property.
• Oramed received a $9.6 million payment from Scilex in accordance with mandatory prepayment requirements under the Senior Secured Promissory Note.

Sentiment

Score: 7

Explanation: The document shows a positive shift in financial performance with a move to net income, driven by financial gains. However, the company is still in a transitional phase with reduced R&D spending and reliance on external financing. The joint venture is a positive development, but its finalization is not guaranteed. Overall, the sentiment is cautiously optimistic.

Positives

• The company achieved a net income of $1.534 million in Q1 2024, a significant improvement from a net loss in the same period last year.
• Financial income increased substantially due to the revaluation of the Scilex transaction and interest from short-term bank deposits.
• The company is actively pursuing a new Phase 3 clinical trial for oral insulin based on positive results in specific patient subpopulations.
• The joint venture with HTIT Biotech provides a significant opportunity for future growth and commercialization of Oramed's technology.
• The company's cash position has improved, providing financial stability for ongoing operations and strategic initiatives.

Negatives

• General and administrative expenses increased by 41% due to higher stock-based compensation expenses.
• The company's research and development activities have been significantly reduced following the termination of the Phase 3 trials.
• There is no assurance that the joint venture agreement with HTIT Biotech will be finalized within the agreed timeline.
• The company is still dependent on external financing to fund its operations and strategic initiatives.

Risks

• The company's future success is dependent on the successful development and commercialization of its oral insulin and other drug delivery technologies.
• The company faces risks related to the joint venture agreement with HTIT Biotech, including the possibility that the agreement may not be finalized.
• The company is subject to the risks associated with clinical trials, including the possibility that future trials may not be successful.
• The company is exposed to potential litigation and the fluctuating market price of Scilex stock.
• The company's operations are affected by the political, economic, and military risks of having operations in Israel.

Future Outlook

Oramed is focused on developing a new Phase 3 clinical trial protocol for oral insulin, evaluating strategic opportunities, and advancing its joint venture with HTIT Biotech. The company expects research and development expenses to remain a major operating expense, but this may change significantly following the strategic review.

Management Comments

• Management believes that it will be able to secure the necessary financing as a result of future third party investments.
• Management believes that it will be able to maintain its current planned activities and the corresponding level of expenditures for at least the next 12 months.
• Management continues to evaluate various financing alternatives for funding new strategic activities, future research and development activities and general and administrative expenses through fundraising in the public or private equity markets.

Industry Context

The announcement comes at a time when there is significant interest in oral drug delivery technologies, particularly for insulin. Oramed's progress in this area is being closely watched by investors and competitors in the pharmaceutical and biotechnology sectors. The joint venture with HTIT Biotech is a strategic move to leverage manufacturing capabilities and expand market reach.

Comparison to Industry Standards

• Oramed's significant reduction in R&D spending following the termination of its Phase 3 trials is a common response in the biotech industry when clinical trials fail to meet endpoints. This is similar to other companies that have had to pivot their strategies after disappointing trial results.
• The company's focus on identifying patient subpopulations that responded well to oral insulin is a strategic approach to salvage value from the failed trials, which is a common practice in the industry.
• The joint venture with HTIT Biotech is a strategic move to leverage manufacturing capabilities and expand market reach, similar to other biotech companies that partner with larger firms to commercialize their products.
• The company's financial performance, with a shift from a net loss to a net income, is a positive sign, but it is important to note that this was largely driven by financial income rather than operational revenue, which is not uncommon for early-stage biotech companies.

Related Party Transactions

• The company has consulting agreements with KNRY Ltd., owned by the Chief Scientific Officer, and Shnida Ltd., through which the President and Chief Executive Officer provides services.

Stakeholder Impact

• Shareholders may view the improved financial results and strategic initiatives positively.
• Employees may be affected by the reduction in research and development activities.
• Customers and partners may be interested in the progress of the oral insulin program and the joint venture.
• Creditors may be reassured by the company's improved cash position and financial stability.

Next Steps

• The company will continue to work on a protocol for a new Phase 3 clinical trial to be submitted to the FDA.
• The company will continue to evaluate potential strategic opportunities.
• The company will work towards finalizing the joint venture agreement with HTIT Biotech.
• The company will continue to monitor the situation in Israel and its potential impact on operations.

Key Dates

Keywords

oral insulin, pharmaceuticals, clinical trials, joint venture, drug delivery, biotechnology, diabetes, ORMD-0801, Scilex, HTIT Biotech